AstraZeneca widens cancer push with up to $500 million Heptares deal

ReutersAstraZeneca widens cancer push with up to $500 million Heptares dealReutersThe companies will also collaborate to discover further A2A receptor-blocking compounds for use in cancer immunotherapy. AstraZeneca is betting on new cancer treatments to revive its fortunes as older medicines go off patent. British-based Heptares ...and more »

Share this post